GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most Americans.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these popular medications.

We talk Ozempic, Wegovy and Mounjaro. A number of studies have shown the amazing weight loss potential of a new group of drugs, known to many by their brand names as Ozempic (which is for diabetes), Wegovy and Mounjaro. But how do these new drugs work? How were they discovered and who can use them?

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of conversations with her husband, Javier. They were in

Hims & Hers Health is set to have a commercial air during Super Bowl LIX. It’s already courting controversy, with calls to bar the game’s host, Fox, from broadcasting it. Why? Experts, advocates and politicians are saying that the 60-second spot — which deems obesity “America’s deadliest epidemic,